Ovarian Pathology

Why it matters

• Ovarian carcinoma is the most lethal gynecologic malignancy in the United States, largely because transcoelomic spread precedes any localizing symptom.
• PCOS is the most common endocrinopathy of reproductive-age women and the leading cause of anovulatory infertility; its consequences (type 2 diabetes, dyslipidemia, endometrial hyperplasia) extend far beyond the ovary.
• Ovarian torsion is a true surgical emergency in which delay costs the gonad.

Epidemiology worth recalling

• Epithelial tumors: account for the large majority of ovarian malignancies; incidence rises after menopause, with median diagnosis in the sixth to seventh decade. Lifetime risk in an average-risk woman is on the order of 1–2%.
• Germ cell tumors: cluster in the first three decades of life; in a patient under 20 with an adnexal mass, germ cell origin is the default assumption.
• Sex cord-stromal tumors: uncommon overall, bimodal (juvenile and adult granulosa cell types), and defined by hormone production rather than by bulk.
• PCOS: affects roughly one in ten reproductive-age women; prevalence varies with the diagnostic criteria applied.
• Functional cysts (follicular, corpus luteum) are by far the most common adnexal finding in premenopausal women and usually resolve spontaneously.

Hereditary / non-modifiable (highest yield)

• BRCA1/BRCA2 germline mutations: loss of homologous recombination repair; BRCA1 confers the higher and earlier ovarian risk. Accounts for the majority of hereditary cases.
• Lynch syndrome (mismatch repair genes): predisposes to endometrioid and clear cell histologies alongside colorectal and endometrial cancer.
• Family history of ovarian, breast, or colorectal cancer; Ashkenazi Jewish ancestry (founder BRCA mutations).
• Increasing age: the dominant risk factor for epithelial cancer.
• Gonadal dysgenesis with a Y-containing line (e.g., 46,XY dysgenesis, Turner mosaicism): gonadoblastoma and dysgerminoma risk — an indication for prophylactic gonadectomy.

"Incessant ovulation" mechanism — each ovulation injures and repairs the surface epithelium and fimbria

• Increases risk: nulliparity, early menarche, late menopause, infertility.
• Decreases risk (modifiable/protective): combined oral contraceptives (protection increases with duration and persists after stopping), multiparity, breastfeeding, tubal ligation, and opportunistic salpingectomy — the last two supporting the fallopian tube origin of high-grade serous cancer.

Chronic inflammation

• Endometriosis: drives the clear cell and endometrioid subtypes through oxidative iron-mediated DNA damage.

Modifiable metabolic/behavioral

• Obesity and cigarette smoking (the latter specifically linked to mucinous tumors).
• Perineal talc exposure is a frequently tested association but the evidence remains inconsistent.

PCOS-specific

• Polygenic susceptibility plus insulin resistance; obesity and physical inactivity are the modifiable amplifiers. Family history is common. Valproate can produce a PCOS-like phenotype.

Torsion risk factors

• An ovarian mass roughly ≥5 cm (especially a mature cystic teratoma, which is buoyant and mobile), pregnancy, and ovulation induction with enlarged ovaries. Torsion of a normal ovary occurs in children with an abnormally long utero-ovarian ligament.

Epithelial cancer — a two-pathway model

• Type II (high-grade serous, ~most deaths): originates not in the ovary but in the fimbriated end of the fallopian tube as a serous tubal intraepithelial carcinoma (STIC). TP53 mutation is essentially universal, and BRCA loss or other homologous recombination deficiency permits accumulation of double-strand breaks. Cells exfoliate onto the ovarian surface and peritoneum. Genomic instability explains both the aggressive course and the exquisite sensitivity to platinum agents and PARP inhibitors (synthetic lethality: block base-excision repair in a cell that cannot perform homologous recombination).
• Type I (low-grade serous, mucinous, endometrioid, clear cell): stepwise progression from benign → borderline → malignant, driven by KRAS, BRAF, PTEN, ARID1A mutations. Indolent, chemoresistant, more often early-stage.

Epithelial ovarian cancer — the postmenopausal woman

• Bloating, increased abdominal girth, early satiety, pelvic or abdominal pain, urinary urgency persisting more than a few weeks. Mechanism: ascites and omental disease, not the ovarian mass itself. These are the symptoms examiners want you to not attribute to IBS.
• Fixed, irregular, solid adnexal mass on bimanual exam; fluid wave/shifting dullness; a sister Mary Joseph nodule at the umbilicus or a left supraclavicular (Virchow) node in advanced disease.
• Pleural effusion from transdiaphragmatic spread → dyspnea.

Germ cell tumor — adolescent or woman in her twenties

• Rapidly enlarging pelvic mass with acute pain, because fast growth stretches the capsule or precipitates torsion/rupture. Often unilateral, often palpable, symptom duration measured in weeks.

Sex cord-stromal tumor — hormone-driven presentation

• Granulosa cell tumor: estrogen excess → postmenopausal bleeding in adults, isosexual precocious puberty in girls.
• Sertoli–Leydig tumor: androgen excess → virilization (deepened voice, clitoromegaly, male-pattern balding) developing over months.
• Fibroma: Meigs syndrome — ovarian fibroma, ascites, and right-sided hydrothorax; a benign tumor mimicking malignancy.

Ovarian torsion

• Sudden, severe, unilateral pelvic pain with nausea and vomiting, often intermittent (torsion–detorsion), in a woman with a known cyst or after ovulation induction. Afebrile early; peritoneal signs suggest necrosis.

PCOS — the classic stem

• Woman in her late teens to twenties with oligomenorrhea or amenorrhea, hirsutism and acne, infertility, often with obesity and acanthosis nigricans (insulin-driven keratinocyte proliferation). Hirsutism reflects free testosterone acting on pilosebaceous units; frank virilization is not typical and should redirect you toward an androgen-secreting tumor or congenital adrenal hyperplasia.

Step 1 — imaging

• Transvaginal ultrasound with Doppler is the initial test for any suspected adnexal mass. Malignant features: solid components, thick septations, papillary projections, internal vascularity, ascites, bilaterality, size. The ACR O-RADS system standardizes this risk stratification.
• Simple, thin-walled, anechoic cysts in a premenopausal woman are almost always functional.
• Torsion: enlarged edematous ovary with peripherally displaced follicles; absent Doppler flow supports the diagnosis but normal flow does not exclude it (dual blood supply). Torsion is a clinical/surgical diagnosis.

Step 2 — serum markers (interpretation, not screening)

• CA-125: most useful in postmenopausal women; falsely elevated premenopausally by endometriosis, fibroids, PID, pregnancy, cirrhosis. Best used to track treatment response and recurrence.
• AFP, β-hCG, LDH in any woman under ~30 with a solid adnexal mass (germ cell panel).
• Inhibin B and AMH for suspected granulosa cell tumor; testosterone/DHEAS for virilization.

Step 3 — referral and staging

• ACOG and the Society of Gynecologic Oncology advise referral to a gynecologic oncologist when imaging, markers, ascites, or family history suggest malignancy — this measurably improves outcomes.
• CT of chest/abdomen/pelvis assesses disease burden.
• Definitive diagnosis and stage are surgical/histologic (FIGO staging at laparotomy with peritoneal washings, omentectomy, and nodal sampling). Do not percutaneously aspirate or biopsy a mass presumed resectable — spillage upstages disease. If disease is unresectable, image-guided biopsy or paracentesis cytology precedes neoadjuvant chemotherapy.

Immediate/emergency

• Ovarian torsion: emergent laparoscopic detorsion with ovarian conservation — even a dusky ovary usually recovers; oophorectomy is reserved for frank necrosis or postmenopausal patients with suspected malignancy. Cystectomy at the same operation reduces recurrence.
• Ruptured hemorrhagic cyst with hemodynamic instability: resuscitate, then surgical hemostasis.

Epithelial ovarian cancer (NCCN framework)

• Primary cytoreductive surgery — total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, staging — aiming for no gross residual disease, which is the strongest modifiable prognostic factor.
• Platinum–taxane chemotherapy (carboplatin plus paclitaxel) adjuvantly; neoadjuvant chemotherapy followed by interval debulking when disease burden or performance status precludes optimal upfront resection.
• Maintenance PARP inhibitors (e.g., olaparib) for BRCA-mutated or homologous recombination–deficient disease; anti-VEGF therapy (bevacizumab) in selected patients.
• Germline and somatic testing for every patient with epithelial ovarian cancer, per NCCN — it dictates PARP inhibitor eligibility and cascade family testing.

PCOS (International Evidence-based PCOS Guideline / ASRM)

• Lifestyle modification first for all patients.
• Not seeking pregnancy: combined oral contraceptive as first-line for cycle regulation, hyperandrogenism, and endometrial protection; add an antiandrogen (spironolactone) for refractory hirsutism, always with reliable contraception because of feminization of a male fetus. Metformin targets metabolic features.
• Seeking pregnancy: letrozole (aromatase inhibitor) is first-line ovulation induction, superior to clomiphene for live birth.

Disease-related — emergencies flagged

• Ovarian torsion (EMERGENCY): venous and lymphatic outflow occlusion precedes arterial compromise → edema, then infarction and loss of the gonad. Signalled by abrupt unilateral pain with vomiting.
• Cyst rupture with hemoperitoneum (EMERGENCY): corpus luteum rupture, worse on anticoagulation; tachycardia, peritonitis, free fluid on ultrasound.
• Malignant bowel obstruction (EMERGENCY): serosal implants and carcinomatosis; the most common terminal event in ovarian cancer.
• Malignant ascites and pleural effusion: VEGF-driven permeability plus lymphatic blockade; cytology-positive pleural fluid defines stage IV.
• Venous thromboembolism: mucin-producing adenocarcinoma promotes tissue-factor–mediated hypercoagulability (Trousseau syndrome).
• Pseudomyxoma peritonei: gelatinous mucinous ascites, most often from a ruptured appendiceal primary rather than a true ovarian mucinous tumor.
• Paraneoplastic syndromes: anti-Yo cerebellar degeneration; anti-NMDA receptor encephalitis with mature cystic teratoma (psychiatric symptoms, seizures, dyskinesias in a young woman — tumor removal is treatment).
• Struma ovarii: thyroid tissue in a teratoma causing thyrotoxicosis.
• PCOS: endometrial hyperplasia and carcinoma from unopposed estrogen; type 2 diabetes, dyslipidemia, obstructive sleep apnea, metabolic dysfunction–associated steatotic liver disease, and obstetric complications (gestational diabetes, preeclampsia).

Treatment-related

• Cisplatin: nephrotoxicity, ototoxicity, peripheral neuropathy (hydrate; amifostine historically used).
• Bleomycin: dose-dependent pulmonary fibrosis — declining DLCO is the sentinel finding; risk amplified by high FiO2.
• Paclitaxel: peripheral neuropathy, hypersensitivity to the vehicle.
• PARP inhibitors: myelosuppression; long-term MDS/AML risk.
• Bevacizumab: hypertension, proteinuria, impaired wound healing, and GI perforation (EMERGENCY).
• Bilateral oophorectomy: abrupt surgical menopause with vasomotor symptoms and accelerated bone loss.
• Ovulation induction: ovarian hyperstimulation syndrome (EMERGENCY) — VEGF-mediated third-spacing with ascites, hemoconcentration, and thrombosis risk; PCOS patients are the highest-risk group.

• High-grade serous carcinoma starts in the fallopian tube fimbria, not the ovarian surface — the STIC lesion, with near-universal TP53 mutation. This is why salpingectomy is protective and why risk-reducing surgery removes tubes and ovaries together.
• Histology buzzwords: psammoma bodies → serous tumors; Call–Exner bodies → granulosa cell tumor; Schiller–Duval bodies (glomeruloid) → yolk sac tumor; Reinke crystals → Sertoli–Leydig; signet ring cells → Krukenberg tumor (bilateral ovarian metastases from gastric adenocarcinoma); sheets of clear cells with lymphocytic stroma → dysgerminoma.
• Single best next step for any suspected adnexal mass is transvaginal ultrasound, not CT and not CA-125. CA-125 is for postmenopausal risk assessment and response monitoring — the USPSTF recommends against screening asymptomatic women.
• Marker → tumor mapping: AFP = yolk sac; β-hCG = choriocarcinoma (dysgerminoma may have mildly elevated hCG from syncytiotrophoblast giant cells); LDH = dysgerminoma; inhibin/AMH = granulosa cell tumor.
• Torsion is a clinical diagnosis — the distractor is "normal Doppler flow rules it out." It does not. Take her to the operating room and detorse rather than resect in a young woman.
• Meigs syndrome (ovarian fibroma + ascites + right hydrothorax) mimics metastatic cancer but is cured by removing a benign tumor.
• PCOS is diagnosed by Rotterdam criteria (2 of 3) after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia. Letrozole is first-line for ovulation induction; the common distractor is metformin. Rapid virilization is not PCOS — look for an androgen-secreting tumor.
• Every woman with epithelial ovarian cancer gets genetic testing per NCCN, regardless of family history, because it determines PARP inhibitor maintenance and family screening.

• Epithelial tumors (serous, mucinous, endometrioid, clear cell) are most common; germ cell tumors more common in young women
• CA-125 is marker for epithelial ovarian cancer; AFP/β-hCG for germ cell tumors
• BRCA1/BRCA2 mutations increase lifetime ovarian cancer risk to 40-50%
• Most ovarian cancers present at Stage III-IV (advanced disease)
• Cystic teratoma (mature teratoma) is most common germ cell tumor in reproductive-age women

Vignette: 58-year-old woman with vague abdominal/pelvic pain, bloating, early satiety, and ascites. Imaging shows complex ovarian mass with peritoneal involvement. Key: Advanced-stage presentation with nonspecific GI symptoms.

• Confusing cystic teratoma with malignant germ cell tumors: Mature teratomas are benign and common in young women; malignant forms (dysgerminoma, yolk sac tumor) are rare and occur in adolescents/young adults with elevated tumor markers
• Missing BRCA counseling: All newly diagnosed ovarian cancer patients should undergo genetic counseling/testing regardless of family history; impacts treatment (PARP inhibitors) and prevention in family members
• Attributing ovarian cancer symptoms to GI disease: Persistent bloating, early satiety, pelvic pain >2 weeks warrants pelvic imaging; don't anchor on IBS or reflux

• Epithelial ovarian cancer: Surgical cytoreduction (goal: <1 cm residual disease) + platinum-taxane chemotherapy (carboplatin + paclitaxel); PARP inhibitors for BRCA+ or homologous recombination-deficient tumors
• Germ cell tumors: Chemotherapy (bleomycin, etoposide, cisplatin [BEP]) with excellent cure rates (>90%); surgery for select cases
• Sex cord-stromal tumors: Surgery ± chemotherapy based on stage/grade
• Benign cystic teratoma: Surgical removal if symptomatic or >5-8 cm; low malignant potential